COVID-19 drives Boehringer’s R&D spend to record level in 2020Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised Share XCOVID-19 drives Boehringer’s R&D spend to record level in 2020https://pharmaphorum.com/news/covid-19-drives-boehringers-rd-spend-to-record-level-in-2020/
Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
COVID-19 bites into Pfizer’s Q3, but biopharma revenues risePfizer is one of the front-runners in the race to approve a COVID-19 vaccine but the US company Share XCOVID-19 bites into Pfizer’s Q3, but biopharma revenues risehttps://pharmaphorum.com/news/covid-bites-into-pfizers-q3-but-biopharma-revenues-rise/
GSK starts 2020 on a high, but warns of tougher times aheadGlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving Share XGSK starts 2020 on a high, but warns of tougher times aheadhttps://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/
Pfizer will start COVID-19 vaccine trial in US next weekPfizer is preparing to start clinical trials of its COVID-19 candidate in the US next week, and says Share XPfizer will start COVID-19 vaccine trial in US next weekhttps://pharmaphorum.com/news/pfizer-will-start-coronavirus-vaccine-trial-in-us-next-week/
Lilly raises 2020 earnings forecast on pandemic stockpilingStockpiling of drugs for chronic diseases like diabetes during the coronavirus pandemic lifted Eli Lilly’s first-quarter results, and Share XLilly raises 2020 earnings forecast on pandemic stockpilinghttps://pharmaphorum.com/news/lilly-raises-2020-earnings-forecast-on-pandemic-stockpiling/
Ozempic acceleration buoys Novo Nordisk, and threatens LillySolid growth for Novo Nordisk’s weekly GLP-1 agonist Ozempic in the fourth quarter helped the Danish drugmaker beat Share XOzempic acceleration buoys Novo Nordisk, and threatens Lillyhttps://pharmaphorum.com/news/ozempic-acceleration-buoys-novo-nordisk-and-threatens-lilly/
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challengeEli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but Share XLilly’s diabetes med Trulicity shrugs off Novo Nordisk challengehttps://pharmaphorum.com/news/lillys-diabetes-med-trulicity-shrugs-off-novo-nordisk-challenge/
Novartis results show Zolgensma early growth wasn’t a flukeNovartis’ bumper crop of new product launches in 2019 helped it post 9% sales growth in the fourth Share XNovartis results show Zolgensma early growth wasn’t a flukehttps://pharmaphorum.com/news/novartis-results-show-zolgensmas-early-growth-wasnt-a-fluke/
